NCT02209441Available不适用
Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
- To determine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of sorafenib in combination with FOLFOX4 (oxaliplatin/leucovorin/5-fluorouracil) as first-line treatment for advanced gastric cancer
- The design of the study incorporated a standard 3 + 3 dose escalation procedure to guide elevation of the sorafenib dosage to the next level
详细描述
-Twice-daily dosing of sorafenib 200 mg in combination with FOLFOX4 proved effective and safe for the treatment of advanced gastric cancer.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age >18 years.
- •documented gastric adenocarcinoma via histological or cytological examinations;
- •newly diagnosed or recurrent unresectable advanced and metastatic gastric cancer;
- •no history of chemotherapy or radiation therapy; at least one lesion with a measurable diameter; -
- •an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
- •an expected survival time of at least 3 months;
- •and provision of informed consent by patients prior to commencement of the study.
排除标准
- •a present or past medical history of other tumors, except for cured skin cancer (non-melanoma) or carcinoma in situ of the cervix;
- •surgery, open biopsy, or obvious trauma within 28 days prior to enrolment; peritoneal seeding or intestinal obstruction;
- •severe gastrointestinal bleeding; grade 1 or greater peripheral neuropathy
- •a past medical history of serious neurological or psychiatric diseases; pregnancy or lactation;
- •women of childbearing potential unwilling to use adequate contraception; a past medical history of heart disease such as greater than grade 2 New York Heart Association (NYHA) congestive heart failure, unstable coronary heart disease (patients having episodes of myocardial infarction earlier than 12 months prior to the study were allowed to enrol), arrhythmia requiring antiarrhythmic therapy (patients on β-blockers or digoxin were allowed to enrol), or uncontrolled hypertension; severe active infection
- •epileptic patients requiring medical treatment (such as corticosteroids or antiepileptic drugs);
- •patients who had received immunotherapy within 4 weeks prior to or throughout the study or had received mitomycin C or nitrourea drugs within 4 weeks previously;
- •allergies or possible allergies to the study medications or other drugs administered during the study;
- •any patient safety or compliance issues that might jeopardize their participation in the study;
- •an inability to swallow oral drugs.
研究者
Shi Yuankai
vice president
Chinese Academy of Medical Sciences
相似试验
终止
1 期
Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT00971126National Health Research Institutes, Taiwan3
已完成
1 期
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal CancerRecurrent Colon CarcinomaRecurrent Rectal CarcinomaStage IVA Colon CancerStage IVA Rectal CancerStage IVB Colon CancerStage IVB Rectal CancerNCT01383343National Cancer Institute (NCI)17
已完成
1 期
Sorafenib in Newly Diagnosed High Grade GliomaGliosarcomaAnaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic OligodendrogliomaGlioblastomaNCT00884416University Hospital, Geneva17
已完成
1 期
Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal CancerMetastatic Colorectal CancerNCT00780169Ottawa Hospital Research Institute16
终止
1 期
Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung CancerLung CancerNCT00543335M.D. Anderson Cancer Center10